Expert Tumor Board to Address Challenging Cases of Relapsed/Refractory Aggressive and Indolent Lymphomas

Registration

Date: Monday, August 9, 2021
Time: 3:00 PM - 5:00 PM HST
Location: Fairmont Orchid - 1 North Kaniku Drive, Kohala Coast, HI 96743 

                 Grande Ballroom

(Live stream opportunities will be available)

Symposium Overview
This live satellite symposium will take place at the 2021 Pan Pacific Lymphoma Conference and will be presented by three renowned experts actively engaged in the care of patients with lymphoma. This symposium will also be live-streamed for those who may not be able to attend in person.

Target Audience
This activity is intended for community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with lymphoma.

Learning Objectives
After participating in the activity, participants should be better able to:

  • Assess current and emerging approaches to the treatment of patients with aggressive B-cell lymphoma, and optimal patient management strategies
  • Evaluate clinical trial data of both approved and novel agents and regimens being investigated in patients with indolent lymphoma
  • Discuss approaches to the care of patients with rare lymphoma subtypes, including Burkitt lymphoma and peripheral T-cell lymphoma   

Continuing Education
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 
The University of Nebraska Medical Center designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Nebraska Medical Center designates this activity for up to 2.0 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.


Agenda
3:00 PM    Welcome, Introduction, and Pre-Session Survey
3:10 PM    Tumor Board #1: Relapsed/Refractory Diffuse Large B-Cell Lymphoma
3:30 PM    Tumor Board #2: Relapsed/Refractory Mantle Cell Lymphoma
3:50 PM    Tumor Board #3: Relapsed/Refractory Follicular Lymphoma
4:10 PM    Tumor Board #4: Other Rare Lymphoma Subtypes
                         Peripheral T-Cell Lymphoma
                          Rare B-cell NHLs (Burkitt Lymphoma, CNS Lymphoma, etc.)
4:30 PM     Audience Q&A
4:50 PM     Recap of Key Points and Post-Session Survey
5:00 PM      Adjourn

Chair
Matthew Lunning, DO, FACP
Associate Professor
Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Faculty
Ranjana Advani, MD
Saul A. Rosenberg Professor of Lymphoma
Physician Leader, Lymphoma Critical Care Program
Stanford Cancer Institute
Palo Alto, California

Andrew Zelenetz, MD, PhD
Medical Director, Quality Informatics
Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medicine
New York, New York

Disclosure Information
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. Faculty (authors, presenters, speakers) are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or other options available when utilizing trade names to ensure impartiality. 

 
All faculty, planners, and others in a position to control continuing education content participating in a UNMC accredited activity are required to disclose all financial relationships with ineligible companies. As defined by the Standards for Integrity and Independence in Accredited Continuing Education, ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating relevant financial relationships in accredited continuing education.  Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations. 
 
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. 
 
All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC. 
 
The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:   

 
Faculty 

Matthew A. Lunning, DO, FACP
Acrotech Biopharma (Self) : Consulting (Status: Ongoing); AstraZeneca/Acerta (Self) : Consultant (Status: Ongoing); Beigene (Self) : Consulting (Status: Ongoing); Bristol Myers Squibb (Self) : Consultant (Status: Ongoing); Bristol-Myers Squibb (Self) : Research Grant Support (Status: Ongoing); Celgene (Self) : Advisory Board (Status: Ongoing), Consulting (Status: Ongoing); Curis (Self) : Research grant support (Status: Ongoing); Daiichi Sankyo (Self) : Consulting (Status: Ongoing); Gilead Sciences (Self) : Consultant (Status: Ongoing); Janssen/Pharmacyclics (Self) : Consultant (Status: Ongoing); Karyopharm (Self) : Consulting (Status: Ongoing); Kite (Self) : Consultant (Status: Ongoing); Legend Pharmaceuticals (Self) : Consulting (Status: Ongoing); Morphosys (Self) : Consulting (Status: Ongoing); Myeloid Therapeutics (Self) : Consulting (Status: Ongoing); Spectrum (Self) : Consulting (Status: Ongoing); TG Therapeutics (Self) : Consultant (Status: Ongoing); Verastem (Self) : Consulting (Status: Ongoing)

Ranjana Advani, MD
Roche (Self): Advisory Board: (Status: Ongoing), Celgene: (Self); Advisory Board: (Status: Ongoing), Takeda: (Self); Advisory Board: (Status: Ongoing), Seattle Genetics: (Self); Advisory Board: (Status Ongoing), Epizyme (Self); Advisory Board: (Status: Ongoing), Sanofi (Self); Advisory Board: (Status: Ongoing), Kura (Self); Advisory Board: (Status: Ongoing), ADCT: (Self); Advisory Board: (Status: Ongoing), Karyopharm; (Self); Advisory Board: (Status: Ongoing); Merck: (Self); Advisory Board: (Status: Ongoing), BMS: (Self); Advisory Board: (Status: Ongoing), Daichi Sanyo: (Self): Advisory Board: (Status: Ongoing); Incyte: (Self); Advisory Board: (Status: Ongoing)

Seattle Genetics: (Self); Institutional research funding (Status: Ongoing), Regeneron: (Self); Institutional research funding: (Status: Ongoing); Pharmacyclics: (Self); Institutional research funding: (Status: Ongoing), Merck: (Self); Institutional research funding: (Status: Ongoing); Forty-Seven: (Self): Institutional research funding: (Status: Ongoing);  Cyteir: (Self); Institutional research funding: (Status: Ongoing); Millennium: (Self); Institutional research funding; (Status: Ongoing); ADCT: (Self); Institutional research funding: (Status: Ongoing);  Kura: (Self); Institutional research funding: (Status: Ongoing)

Andrew D. Zelentz, MD. PhD
AbbVie (Self) : Consultant (Status: Ongoing); Adaptive Biotechnology (Self) : Consultant (Status: Ongoing); Amgen (Self) : Consultant (Status: Ongoing); Astra Zeneca (Self) : Consultant (Status: Ongoing); Beigene (Self) : DMC Chair (Status: Ongoing), Research (Status: Ongoing); Bristol Myers Squibb (Self) : DMC Member (Status: Ongoing); Celgene (Self) : Consultant (Status: Ongoing), DMC Member (Status: Ongoing); Gilead (Self) : Consultant (Status: Ongoing), Research (Status: Ongoing); Janssen (Self) : Consultant (Status: Ongoing); Juno (Self) : DMC Member (Status: Ongoing); Mei Pharma (Self) : Consultant (Status: Ongoing), Research (Status: Ongoing); Morphosys (Self) : Consultant (Status: Ongoing); Novartis (Self) : Consultant (Status: Ongoing); Roche (Self) : Research (Status: Ongoing); Roche/Genentech (Self) : Consultant (Status: Ongoing)


Planning Committee​
The following planning committee members have nothing to disclose:​
UNMC: Brenda Ram, CMP, CHCP​; Valeta Creason-Wahl, HMCC; Renee Paulin, MSN, RN, CWOCN
Bio Ascend: Chloe Dunnam; Dru Dace, PhD; Kraig Steubing

Support
This activity is supported by independent educational grants from Daiichi-Sankyo, Inc., Genentech, a member of the Roche Group, MorphoSys, and TG Therapeutics, Inc.

Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.